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Many similarities exist between the exogenous nitrates and
endethelium-derived relaxing factor, which is nitric oalde or a
thiot derivative. Both act by way of guany)nte cyclaw, which
increases intracellular concentrations of cyclic guanusine mono-
phosphate,
resulting in smooth muscle cell rdantion and
anti-
platelet
effects . Thiols may be important in the
of exogenous nitrates and other intracellular pnwesses involving
Since the first description of the therapeutic use of glyceryl
trinitrate appeared in 1879 (1), organic nitrates have re-
mained the cornerstone for the treatment of angina pectoris .
Over the past decade, emphasis has been placed on research
to elucidate the subcellular mechanisms of these com-
pounds. During the same period, key discoveries have
shown that the vascular endothelium plays a pivotal role in
the local control of vasomotor tone, primarily through the
synthesis and release of endothelium-derived relaxing factor
(2) . 'This substance has now been identified as nitric oxide or
a related nitrosothiol whose actions parallel those of organic
nitiovasodilators (3-5) . This review discusses the nature of
nitric oxide and the mechanism of action of nitric oxide and
organic nitrates and explores the interactions that might
exist between them .
Chemical Nature of100hytheliumn-Derived.
Relaxing Factor
In 1980, Furchgott and Zawadzki (2) discovered that the
aoety[choline-induced relaxation of rabbit aortic strips re-
quired an intact endothelium. They concluded that acetyl-
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nitric oxide. As such, important interactions might be expected
between nitrates and endothelium-dependent processes that in-
volve nitric oxide. TIds review explores the mechanisms of action,
biologic effects and potential interactions between nitrates and endo-
thelium-derives) relaxing factor
.
(j Am Call Cardiol 1994,24.555-66)
choline stimulated muscarinic receptors on the endothelium,
leading to the release of a nonprostanoid relaxing factor,
which they named endothelium-derived relaxing factor .
A diffusible substance with a half-life of several seconds,
(6,7) endothelium-derived relaxing factor could be inhibited
by hence-containing proteins (8), and it was destroyed by
oxygen free radicals (10) . It also activated soluble guanylate
cyclase and increased the concentration of cyclic guanosine
monophosphate (cyclic GIMP) (10) . Collectively, these char-
acteristics led to the simultaneous observation by Ignarro et
al . (4) and Furchgott and Khan (5) that endothelium-derived
relaxing factor was strikingly similar to nitric oxide .
The first proof that nitric oxide was at least one of the
relaxing factors resulted from studies by Paltrier et al . (11) .
Using a chemiluminescence assay, they demonstrated that
cultured endothelial cells release nitric oxide when exposed
to bradykinin . In this assay, nitric oxide is specifically
detected by its reaction with ozone . Results of these studies
provided strong evidence that endothelium-derived relaxing
factor is nitric oxide or a chemically related compound .
Recent findings suggest that endothelium-derived relaxing
factor may also be similar to a labile nitroso compound
(S-nitroso-L-cysteine) (3,12) .
Mechanism of Action of Endothelium-
Derived Relaxing Factor and
Organic Nitrates
Endothelium-derived relaxing factor . The mechanism of
action of nitric oxide has been examined in considerable
detail (10,13) . Palmer et al . (14) have demonstrated that
nitric oxide is synthesized from the guanidino nitrogen of the
amino acid L-arginine . This conversion is controlled by an
enzyme, nitric oxide synthase, which can be stimulated by a
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number of physical and chemical stimuli and is inhibited by
several arginine analogs, including N°-monomethyl-L-
arginine
. Receptors on' he endothelial cell membrane mod-
ulate this interaction in association with signal transduction
proteins (the G protein family) (15) . Serotonin receptors, for
example, interact with the pertussis-sensitive inhibitory pro-
tein (G;) to modulate release of nitric oxide
(16) . After
release from the endothelium, endothelium-derived relaxing
factor diffuses across the extracellular space into the smooth
muscle cell and utilizes the guanylate cyclase second-
messenger system to implement its biologic actions . Both
nitric oxide and endothelium-derived relaxing factor have
been shown to activate soluble guanylate cyclase, leading to
an increase in the intracellular concentration of cyclic GMP
(10,17).
Cycic guanoalne 3'-,5'-momphosphate system: intraccellu-
lar d r. Cyclic GMP is formed from guanosine
5'-triphosphate by the activation of guanylate cyclase, of
which there are at least three distinct types: 1) soluble
guanylate cyclase, which is activated by nitric oxide and
organic nitrates ; 2) membrane-bound (particulate) guanylate
cyclase, which is induced by atrial natriuretic peptide ; and 3)
cytoskeleton guanylate cyclase, which is sensitive to E. coil
heat-stable enterotoxin (18) . Purified soluble guanylate cy-
clase has been shown to contain heme, which is now thought
to be the receptor site for nitric oxide on soluble guanylate
cyclase (19-21) . Electron paramagnetic resonance studies
have demonstrated that the binding of nitric oxide to heme
results in a structural change of the hence molecule in which
the iron atom protrudes out of the plane of the protoporphy-
rin ring (22) . Local thiol groups are necessary to reduce the
heme iron atom to the ferrous state, thus facilitating the
nitric oxide-heme interaction .
The net result of the activation of soluble guanylate
cyclase is the formation of cyclic GMP, which then activates
a serinelthreonine protein kinase (cG-Pk) (23) . Several pro-
teins may be phosphorylated by cG-Pk, resulting in smooth
muscle relaxation. Cyclic GMP also stimulates calcium
efflux and uptake by intracellular stores . It may also inhibit
calcium influx across the plasma membrane by decreasing
production of diacyl glycerol (DAG) and inositol 1,4,5-
triphosphate (IP3), which results in a decrease in protein
kinase C activity (Fig . 1) (24) . The effects of cyclic GASP are
terminated by a specific phosphodiesterase (25) .
Several inhibitors of this pathway have been utilized in
studies examining the mechanism of action of endothelium-
derived relaxing factor
. Because of the natural affinity of
nitric oxide for heme rings, free reduced hemoglobin has
been used as an inhibitor of both endothelium-derived relax-
ing factor (8,26) and nitric oxide (27) . Methylene blue has
also been used to inhibit endothelium-derived relaxing factor
by the direct inhibition of guanylate cyclase or by the
generation of superoxide free radicals (28,29) .
Does. The nitrate compounds used in the treat-
ment of angina have been termed organic nitrovasodilators
because they possess a nitrate ester bond (R-0--nitric
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oxides) (Fig . 2). This distinguishes them from nitric oxide-
containing compounds without an ester bond, such as nitro-
prusside. Important similarities and differences exist in the
biotransformation of these organic and inorganic nitrates, but it
is generally accepted that they share a final cnnunon pathway
wish endothelium-derived relaxing factor .
The mechanism by which nitroprusside releases nitric
oxide has recently been reported . It has been previously
thought that nitric oxide release occurred spontaneously
(30) . However, more recently Bates et al . (31) have reported
that a one-electron reduction with accompanying cyanide
loss was required before nitric oxide could be released .
The biotramtsformation of organic nitrates is probably
more complex . Although there is much controversy about
the role of thiols, they may be important at several levels in
the nitrate/nitric oxide pathway including 1) the formation of
S-nitrosothiol intermediaries, and 2) the activation of soluble
guanylate cyclase by nitric oxide . The formation of nitro-
sothiol intermediaries from organic nitrates seems to depend
on the denitrification of the R-0-nitric oxide, to a reactive
thiol intermediary (32,33) . Using a rat model of tolerance,
Fung et al. (34) showed that the beneficial effect of the thiol
donor N-acetylcysteine on nitroglycerin might be mediated
by extracellular S-nitrosothiol formation in addition to intra-
cellular thiol repletion . A recent study in rats, which used
various thiol donors and depleting agents, demonstrated that
both intracellular and extracellular thiols are important in
modulating the effect of nitroglycerin in vivo (35) . Although
suggestive, it has not been shown conclusively that nitro-
sothiols are intermediaries in the biotransfcrmation process .
Recent data by Chung and Fang (36) have demonstrated
that nitrates are enzymatically converted to yield nitric oxide
by a surface membrane enzyme system that is not identical
to that provided by glutathione-S-transferases (37). It has
been suggested by these investigators and others (38) that
sulfhydryl.donating compounds may act instead as cofactors
in the enzymatic transformation of organic nitrates .
Thiols have also been shown to be potentially important
for the antiplatelet effect of the nitrovasodilators . Loscalzo
(39) demonstrated that N-acetylcysteine potentiated the
platelet inhibitory actions of nitroglycerin by inducing the
formation of S-nitroso-N-acetylcysteine . A recent study has
reported that the liberation of nitric oxide from isosorbide
dinitrate (ISDN) and nitroglycerin is potentiated by cysteine
(40). In contrast, the release of nitric oxide from nitroprus-
side was reported to be independent of cysteine (41) . How-
ever, thiols can also potentiate the antiplatelet effects of
nitroprusside, which suggests that they have an important
role at other levels (42) . The fact that added thiols potentiate
antiplatelet effects does not prove that an important relation
exists between thiols and nitrates in vivo in the absence of
administered thiols .
The binding of nitric oxide to the home moiety of soluble
guanylate cyclase and the activation of cyclic GMP follows
the same pathway as that described for endothelium-derived
relaxing factor (10) . A recent study in pigs demonstrated
JACC Vol . 24, No . 2
August 1994 :555-66
Figure 1 . A, Proposed mechanisms by which nitrouo
compounds are bioconvc,rted to nitric oxide, which binds
to the heme moiety of guanylate cyciase (GC), leading to
increases in intracellular levels of cyclic guanosine mono-
phosphate (CGMP) . Reprinted, with permission, from
Statnler and Loscalzo (127) . B, Schemata showing some
of the potential sites of action of cyclic guanosine mono-
phosphate-mediating vascular smooth muscle cell relax-
ation. Reprinted, with permission, from Ahlner et . al .
(112) . See text for details. ATPasc = adenosine triphos-
phatase ; DAG = diacyl glycerol ; GTI' = guanosine
triphosphate ; HONO = nitrous acid : tP- = inositol 1,4,5-
triphosphate ; MIIC = myosic heavy chain; MLC
myosin light chain ; htLC1C, = myosin lib ht chain kinase
with active enzyme ; MLCK
I = MLCK with inactive
enzyme; NO = nitric oxide ; NO = nitrite ; NTG =
nitroglycerin ; PIP, = phosphatidyl inositol biphosphate ;
Pk-C = protein kinase C ; R-ON02 = organic nitrate ;
RSH = reduced thiol ; RSNO = S-nitrosothiol ; RSSR =
disulfide.
B
inhibition of the antiplatelet effect of nitroglycerin by meth-
ylene blue, along with a documented decrease in cyclic CMP
level (43) . A similar study in humans also demonstrated that
nitroglycerin was capable of increasing platelet cyclic CMP
levels and that the degree of vasodilation correlated with
these levels ;44) . These studies support the view that the
guanylate cyclase system is the final pathway for the action-,
of all nitrovasodilators .
Differences in tolerance between organic nitrates and nitro-
prussiide. A detailed discussion of tolerance is beyond the
scope of this review . Continuous administration of organic
nitrates leads to tolerance to their hemodynamic and clinical
effects. Needleman et al . (45,46) demonstrated that arterial
strips require the presence of tissue thiol groups to relax to
nitroglycerin and nitroprusside. Numerous other studies
have demonstrated that thiol group donors, such as cysteine
and glutathione, can potentiate guanylate cyclase activation
by both nitrates and nitroprusside (41,47-49) . Moreover,
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Figure 2. Chemical structure of selected nitrovasodilators
. GTN glyceryl trinitrate; ISDN = isosorbide dinit,ate : IS-5-M  = iso-
sorbide 5-mononitrate
; NP = nitroprusside, Reprinted, with permis-
sion, from Ahlner et al . (112) .
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studies have demonstrated that the administration of thiol
donors, such as N-acetylcysteine, or thiol-containing angio-
tensin-converting enzyme inhibitors, such as captopril, can
result in the reversal of nitrate tolerance or the potentiation
of nitrate effects in smooth muscle cell preparations (50,51),
intact animals (33,52) and clinical studies (53-56) . The sulf-
hydryl depletion hypothesis, which has indirect support from
the previous Aata, is now thought to be incomplete, however.
Vascular sun lydrl groups are not decreased during develop-
ment of nitroglycerin tolerance (57). The recent data by Fung
(58) that show that nitrates are enzymatically converted in
smooth muscle cells to nitric oxide have lead to the evolution of
the thiol-depletion hypothesis . It may be that tolerance is due
in part to a decrease in available sulfhydryl groups to interact
with enzymes that are necessary for metabolic activation of
citrates .
It is also clear that long-term nitrate administration is
accompanied by a variety of compensatory physiologic effects .
including increased plasma concentrations of renin and cate-
cho] ` s, increased body water and shifts in vascular vol-
ume (59--61) . It is likely that tolerance is a complex process
involving both cellular and physiologic processes .
Cellular tolerance has not been shown to be a major
problem for nitroprusside . Nitric oxide is released from nitro-
prusside by one-electron transfer and may interact with differ-
ent pools ofthiols than those required for the transformation of
organic nitrates, but this has not been definitively proved (40) .
Biologic Actions of Endothelia - recd
Relaxing Factor
Conduit vends. The endothelium modulates vascular
tone by releasing various relaxing factors (i .e ., endothelium-
derived relaxing factor, endothelium-derived hyperpolariz-
ing factor and prostacyclin) and the contracting factors (i .e.,
thromboxane-A2, free radicals, endothelium-derived con-
tracting factors and endothelin) (62,63) . Endothelium-
derived relaxing factor can be released in response to a
variety of stimuli, including shear stress and pressure, ag-
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Figure 3. Recent change in vessel diameter with acetylcholine
plotted in (A) atherosclerotic and (B) normal coronary arteries .
In both the prestenotic and stenotic segments, profound vaso-
constriction was seen with acetylcholine, whereas n normal
vessels dilation was seen with acetylcholine . This represents
endothelial dysfunction in atherosclerotic coronary arteries .
ACh = response to maximal dose of acetylcholine ; Cl. _
control ; C2 = vehicle control, C3 = repeated control ; TNG =
nitroglycerin. *p < 0.01 . Reprinted, with permission, from
Ludmer et al . (74) .
gregating platelets, thrombin, adenosine diphosphate (ADP),
serotonin, bradykinin, histamine, norepinephrine, vasopres-
sin, substance P and acetylcholine (64) .
Experimental evidence . A substantial body of basic re-
search has established the importance of endothelium-
derived relaxing factor in both basal and stimulated control
of vascular tone in large conduit vessels . Studies have
demonstrated that basal cyclic GMP levels are higher in
aortic strips when the endothelium is intact than when it has
been denuded (8), and bioassay techniques have also dem-
onstrated the basal release of nitric oxide from large conduit
vessels. The role of endothelium-derived relaxing factor as
the mediator of vasodilation is supported by experiments
that used endothelium-dependent agonists in the presence of
inhibitors of endothelium-derived relaxing factor (8) .
Increasing flow is also an important stimulus of endothe-
lium-dependent vasodilation. It has been shown in the ca-
nine femoral and coronary artery that removal of the endo-
thelium by balloon injury prevents the flow-mediated
increase in diameter, demonstrating that the response is
endothelium dependent (65-68) .
Human studies . In vitro studies using human coronary
arteries have shown endothelium-dependent relaxation in
response to acetylcholine in normal arteries and impaired
relaxation in atherosclerotic coronary arteries (69-71) . In
vivo studies of conduit vessel vasomotion have focused on
the brachial, femoral and coronary circulation (72-74) . l ud-
mer et al. (74) demonstrated coronary vasodilation in re-
sponse to acetyicholine in patients with normal coronary
arteries and no risk factors for atherosclerosis, but vasocon-
striction occurred in patients with atherosclerosis (Fig . 3) .
This was the first study to recognize that endothelium-
dependent vasodilation does exist in vivo in normal human
subjects and is impaired in patients with atherosclerosis . A
number of subsequent studies also showed that other ago-
nists, including substance P, serotonin and histamine, can
increase the coronary artery diameter in normal subjects
(75-77). Studies using inhibitors of nitric oxide and nitric
A
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oxide synthase have confirmed that nitric oxide mediates
acety1choline-induced coronary artery dilation (69,78,79) .
Flow-mediated vasodilation has also been demonstrated
in human femoral, brachial and coronary arteries (72,80,81) .
Physiologic stimuli that lead to an increase in coronary blood
flow, including the use of papaverine or adenosine (82,83),
bicycle exercise testing (84), cold pressor testing (85,86) and
mental arithmetic (87), have all been shown to increase
coronary artery diameter in patients without atherosclerosis
or risk factors . An impaired response is seen in patients with
atherosclerosis . The parallel response of coronary arteries to
the physiologic stimuli and to acetylcholine led investigators
to the conclusion that these stimuli were endothelium depen-
dent. However, studies using nitric oxide inhibitors have not
been done to confirm the role of nitric oxide in flow-mediated
vasodilation in the coronary circulation .
Resistance vessels . Experimental studies . In vitro studies
that used microscopy have demonstrated dilation of resis-
tance vessels in response to acetylcholine from rabbit ear
(88), rat cremaster muscle (89) and canine coronary resis-
tance vessels (90) . In vivo studies using rabbit hind limbs or
isolated buffer-perfused rabbit heart and primate studies
using nitric oxide inhibitors have confirmed that nitric oxide
mediates vasodilation in the microcirculation (91-94) .
Studies that used systemic doses of 0-monomethyl-L-
arginine have shown an increase in blood pressure and reflex
bradycardia in the rabbit (95), rat (96) and guinea pig (97),
suggesting that the basal release of endothelium-derived
relaxing factor is important at the resistance vessel level in
regulating systemic blood pressure .
Human studies . Vasodilation in resistance vessels in vivo
is assessed by measuring blood flow . For a constant pressure,
"tone" in the resistance vessels is the major determinant of
flow. Importantly, any stimulus that relaxes resistance vessels
and increases flow will result in a mild increase in conduit
vessel diameter as a consequence of flow-mediated vasodila-
tion . Resistance vessel dilation therefore effects changes in
conduit vessels through flow-mediated dilation .
Cholinergic agonists infused into the brachial artery are
known to increase flow as measured by impedance plethys-
mography. Valiance et al . (98) demonstrated that this
response could be attenuated by the infusion of 0-
monomethyl-L-arginine, which suggests that the dilator ac-
tion of endothelium-derived relaxing factor contributes to
the stimulated regional blood flow response to acetylcholine .
In the coronary circulation, the blood flow response to
acetylcholine and substance P is impaired in the microvas-
culature of patients with nonobstructive coronary artery
disease (99,100). Lefroy et al . (79) used coronary sinus
oxygen saturation as a measure of coronary blood flow to
demonstrate that NG-menomethyl-L-arginine did not abolish
the blood flow increase in response to acetylcholine . They
suggested that endothelium-derived relaxing factor may not
be the only mediator of acetylcholine-induced increase in
blood flow in the coronary microvasculature . Other media-
tors, such as endothelium-derived hyperpolarizing factor,
ANDERSON ET AL
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may be involved, or the contribution of nitric oxide is small
and was not detected because of the inherent variance in a
biologic system .
Basal effects of endothelium-derived relaxing factor on
the microvasculature in humans have been addressed by
studies using endothelium-derived relaxing factor inhibitors .
Valiance et al . (98) demonstrated a 50% decrease in forearm
blood flow to locally infused N °-monomethyl-L-arginine,
which suggests a role for endothelium-derived relaxing fac-
tor in the maintenance of resistance vessel tone . Lefroy et al .
(79) showed that NG-monomethyl-L-arginine produced only
a small, nonsignificant decrease in basal flow . Thus, it is
generally believed that endothelium-derived relaxing factor
plays a role in the stimulated and basal maintenance of tone
in the resistance vessels, but the story is far from complete .
Platelet function. The antiplatelet effects of nitric oxide
and endothelium-derived relaxing factor have been known
for some time (42,101) . The role of endothelium-derived
relaxing factor as an antiadhesive agent was Aiovin by
Radomski et al . (102) and may be an important action of
endothelium-derived relaxing factor because prostacyclin
has potent antiaggregatory properties but only mildly
antiadbcsive function. There is additional evidence that
.P.1ot'helium-derived relaxing factor can disaggregate plate-
lets (42), and prostacyclin has been shown to potentiate
this andaggregating and disaggregating activity (102,103) .
Endothelium-derived relaxing factor is also known to in-
crease cyclic guanosine monophosphate level in platelets,
but the mechanism by which this inhibits platelet aggregation
and adhesion is poorly understood . Studies have suggested
that a reduction in calcium influx may inhibit the phospho-
lipase C stimulation of protein kinase C (104,105) .
Nitric oxide subserves the antithrombotic process by mech-
anisms other than its antiaggregatory and antiadhesive proper-
ties. The release products of "activated platelets" mediate
changes in vasomotor tone in part through endothelium-
dependent mechanisms . These factors, which in general result
in vasodilatation if the endothelium is intact, have been shown
to p--oduce constriction in patients with atherosclerosis
(76,106,107) . Thus, the released platelet products can amplify
the ischemic effects by causing constriction at sites of endo-
thelial dysfunction . This adverse platelet-endothelium interac-
tion is an important cause of vasoconstriction at sites of platelet
aggregation.
Other actions. Although the major actions of eradothelium-
derived relaxing factor are related to its effect on vasomotion
and platelet function, a number of other actions have been
reported. Several studies have reported that endothelium-
derived relaxing factor is cytoprotective and has an antipro-
liferative effect on smooth muscle cells (108-111). New
interest has now been focused on the ability of endothelium-
derived relaxing factor released from the myocardial cells to
regulate local inotropy . Studies of septic shock suggest that
vasodilation and decreased inotropy may resu!t in hypoten-
sion because of the systemic release of large quantities of
endothelium-derived relaxing factor . As a result of the
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ubiquity of endothelium-derived relaxing factor, many new
roles are likely to be discovered from future research .
Biologic E . sects of Org ic. Nitrates
The actions of the organic nitrovasodilators parallel those
of endothelium-derived relaxing factor . Major research ef-
forts have focused on their ability to dilate coronary arteries
and systemic arteries and veins and more recently on their
ability to inhibit platelet aggregation .
V r smooth m _ .
The major action of organic
nitrates is the dilation of vascular smooth muscle in arteries
and veins (112). The magnitude of this effect depends on the
type of preparation studied and the nitrate preparation used .
Nitroglycerin tends to exhibit a biphasic relaxation pattern,
whereas isosorbide dinitrate and isosorbide-5-mononitrate
(IS-5-MN) have no such biphasic response (113) . Nitroglyc-
erin has a greater sensitivity for veins than arteries (114) . An
in vitro study comparing the vasorelaxant effects of nitro-
glycerin, isosorbide dinitrate and isosorbide-5-mononitrate
on isolated renal arteries and veins from rabbits suggested
that the latter two were even more venoselective than
nitroglycerin (115,116) . Most in vitro studies have demon-
strated that therapeutic doses of nitrates have only a small
relaxing effect on peripheral arteries (117) .
In vi" studies in animals, normal volunteers and patients
with coronary artery disease, both with and without conges-
tive heart failure have consistently shown that venous ca-
pacitance vessels have the highest sensitivity to nitrates
(112) . This venodilation leads to a reduction in cardiac
preload with a decrease iri left ventricular volume and filling
pressure that results in r1 decrease in oxygen consumption .
The magnitude of the decrease in these variables is in the
map 2 to 40%.
Inpatients with heart failure, sufficient arterial unloading
occurs to actually increase cardiac output. The in vivo effect
on compliance changes in large arteries may be greater than
that predicted from in vitro studies (118) .
Cdr artery dila . A number of studies demon-
strate that nitrates are potent dilators of both normal and
atherosclerotic coronary arteries, a mechanism that may
potentially increase blood flow to the myocardium . Feldman
et al . (119) have shown that intracoronary doses of nitroglyc-
erin can increase coronary artery diameter by 10% to
30%o
.
Low doses of intravenous or sublingual nitroglycerin have
also been shown to dilate coronary stenoses compared with
placebo infusions (120,121) . Brown et al . (122) subsequently
demonstrated that -75 of stenoses will dilate to some
extent in response to nitroglycerin and suggested that this
resulted from dilation of the normal portion of the artery in
eccentric stenoses. Feldman et al. (123) also showed that
dilation of collateral vessels was possible after nitrate ad-
ministration. Reversal of distal or collateral vessel constric-
tion, which may occur during exercise, may be another
important mechanism by which nitroglycerin works
(124,125). The extent to which epicardial coronary dilation
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relieves angina, however, remains controversial, although it
probably plays some role .
One of the interesting aspects about organic nitrates is
their relative inability to dilate small coronary arterioles in
vitro. The response to nitroglycerin in vessels <I 00 gm can
be brought out by incubation with thiols, implying that small
vessels have an inability to convert nitroglycerin to its
vasoactive metabolite . This remains speculative at present
and has been nicely reviewed by Harrison and Bates (38) .
Despite this, however, nitrates may increase coronary flow
by 25% to 50%, suggesting a mild effect on larger coronary
resistance vessels (54,56,126) . This effect is transient only
and avoids the potentially deleterious coronary steal phe-
nomenon that may be seen with potent arteriolar vaso-
dilators.
Platelet effects. The effect of organic nitrates on platelet
function has recently been reviewed (127). In vitro studies
beginning in the late i s uniformly demonstrated an an-
ti regatory effect of nitroglycerin on platelets (118, 129) . It
was also known that nitroprusside can directly inhibit plate-
let aggregation and promote disc gction (130,131) .
As is the case for endothelium-derived relaxing factor,
several groups have reported synergistic actions between the
antiplatelet effects of nitroglycerin and nitroprusside with
prostacyclin (132,133) . In vitro studies using supraphysio-
logic concentrations have demonstrated that prostaglandin-
mediated pathways may be important for the antiplatelet
effects of nitrates (129,134,135) .
Folts et al . (136) used an in vivo canine coronary model to
demonstrate that platelet aggregation and dislodgment can
be inhibited by nitroglycerin and that this effect may be
mediated by cyclic GMP. Lam et al . (137) demonstrated that
nitroglycerin can decrease platelet deposition in the common
carotid arteries of balloon-injured pigs . Both studies demon-
strated that the antiplatelet effect paralleled the hemody-
namic changes induced by nitroglycerin . However, initial in
vivo human studies failed to demonstrate an antiplatelet
effect for the organic nitrates at physiologic concentrations
(138) . Stamler et al. (139) investigated the effect of intrave-
nous nitroglycerin on platelets ex vivo. They found that in
vivo infusions of nitroglycerin titrated to the hemodynamic
response did not alter ADP-induced platelet a regation .
However, after they added N-acetylcysteine (a thiol donor)
ex vivo, platelet inhibition was seen . Diodati et al . (140) used
bedside impedance aggregometry before and after 45 min of
nitroglycerin infusion and demonstrated a decrease in the
area under the a . .regation curve in response to ADP and
thrombin, suggesting an antiplatelet effect . They also re-
ported that if blood was left to stand for 30 min before
analysis, no difference was noted between the control and
nitroglycerin infusion (140) . They believed that prolonged
ex vivo experiments usually led to depletion of thiol
groups and was a possible explanation for some of the
previously negative results from studies using nitroglycerin
(131,139,141). Another recently reported in vivo study (44)
was able to demonstrate a good relation between platelet
JACC Vol. 24, No
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cyclic GMP levels and coronary vasodilatien to sublinguall
nitroglycerin in patients with and without nitrate tolerance .
It is likely, but not conclusive, that nitrates have a beneficial
antiplatelet effect in in vivo situations .
Endothelial Dysfunction :
NO% hiechanisims
Endothelial vasodilator dysfunction has been demon-
strated in vitro and in vivo in animal and human studies in a
wide range of conditions, including hypercholesterolealia,
atherosclerosis, hypertension, diabetes mellitus, heart fail-
ure and postischemic reperfusion. A detailed discussion is
beyond the scope of this article, but several reviews are
available (63). The mechanism of this vasodilator dysfunc-
tion is unclear, and because the actions of endothelium-
derived relaxing factor are complex, abnormalities could
occur at many sites of action: 1) impairment of endothelial
membrane receptors that interact with agonists or physio-
logic stimuli to release nitric oxide ; 2) diminished levels or
impaired utilization of L-arginine, the substrate for nitric
oxide synthesis ; 3) reductions in nitric oxide synthase, the
enzyme responsible for the conversion of L-arginine to nitric
oxide; 4) impaired release of nitric oxide from the endothe-
lium in its most active form (i .e ., nitrosothiols) ; 5) enhanced
degradation of nitric oxide by oxygen free radicals ; 6)
impaired transport from endothelium to smooth muscle cell
(functional barrier) ; 7) impaired interaction of nitric oxide
with guanylate cyclas,,. and subsequent increase in cyclic
GMP; and 8) decrease in generalized smooth muscle cell
sensitivity to vasodilators .
The best studied conditions associated with endothelial
dysfunction are hypercholesterolemia and atherosclerosis .
Hypercholesterolemia inhibits endothelium-dependent re-
laxation evoked by receptor-dependent stimuli, but this
generally does not inhibit the direct relaxing effect of nitro-
glycerin. Studies in hypercholesterolemic porcine coronary
arteries have demonstrated that the activity of the pertussis
toxin-sensitive G i protein-dependent receptor pathway is
reduced in hypercholesterolemic endothelial cells (142,143) .
This may be one of the mechanisms of endothelial dysfunc-
tion in the early stages of the atherosclerotic process (144) .
The synthesis of nitric oxide involves the oxidation of a
guanidino nitrogen on L-arginine by means of specific nitric
oxide synthases. Several groups have suggested that a
depletion of L-arginine is responsible for this endothelial
dysfunction in hypercholesterolemia . It was shown in rabbit
hind limbs that L-arginine administration potentiated the
acetylcholine-induced increase in hind limb flow in rabbits
with dietary hypercholesterolemia (145) . Creager et al .
(146,147) also demonstrated that an infusion of L-arginine
improved the forearm blood flow response to methacholine
in hypercholesterolemic patients . Two similar studies have
been performed in human coronary arteries . Drexler et al .
(148) were able to demonstrate an improvement in the flow
response to acetylcholine after L-arginine infusion but did
not demonstrate any effect on large-vessel vasomotion, In
contrast, Dubois-Rande et al. (149) showed an improvement
in large-vessel response to acetylcholine after
L-Rrghqir1e
infusion . Therefore, in certain situations, depletion or
impaired utilization of L-arginine may contribute to the
dysfunction seen in hypercholesterolemia ; however, a defi-
ciency of the
substrate has not been proved by measure-
ments of intracellular concentrations .
Rubanyi and Vanhoutte (9) have shown that superoxide
anions can inactivate endothelium-derived relaxing factor
.
In states in which excessive free radicals are generated, an
increase in oxidation of low density lipoproteins (LDLs)
would also result
. Oxidized LDL itself has been shown to be
a potent inhibitor of endothelium-dependent relaxation
through mechanisms that are transduction dependent
(150,151) . Still others have suggested that free radicals
interfere with the production of potent vasodilators and may
lead to increased destruction of endothelium-derived relax-
ing factor (152) . A recent study has shown that superoxide
dismutase can attenuate the vasoconstricting effect of ace-
tylcholine in the coronary arteries of patients with athero-
sclerosis (153), suggesting a role for oxygen free radicals in
the inactivation of nitric oxide in vivo .
A defect in the vascular smooth muscle of resistance vessels
in relation to the action of endothelium-derived relaxing factor
has been suggested by two recent forearm studies . Creager et
al . (146) demonstrated a decrease in the stimulated increase in
flow in response to methacholine and nitroprusside in patients
with hypercholesterolemia compared with control subjects .
Calver and Valiance (154) also demonstrated a decrease in flow
response to nilroprusside in patients with type I diabetes
mellitus compared with control subjects . These studies did not
determine whether the attenuated responses seen with nitro-
prusside are the result of augmented inactivation of nitric oxide
from nitroprusside or are a generalized defect in smooth
muscle cell function.
Other mechanisms of endothelial dysfunction include
intimal thickening, which acts as a barrier to the diffusion of
endothelium-derived relaxing factor (155) and the increased
production of vasoconstrictor substances that offset the
balance toward vasoconstriction . Endothelin may be one
such factor. However, the role of these vasoconstrictors has
not been well defined . Thus, even though the normal phys-
iology of endothelium-derived relaxing factor has been ex-
tensively studied, the mechanisms involved in its failure are
incompletely understood at this time .
Interactions Between Exogenous
Vitro- asodilators and
Endothelia
	
erived
Relaxing Factor
Extensive evidence is available to show that the chemical
nature, mechanism of action and biologic actions of
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endothelium-derived relaxing factor and the organic nitrates
parallei each other. However, it is not known whether the
administration of exogenous nitrates has an advantageous or
potentially deleterious effect on
the endothelium-dependent
nitric oxide pathway or whether exogenous nitrates can
replace the decreased activity of endogenous nitric oxide in
various diseases . Moreover, it is unclear whether endothelial
dysfunction affects the response of exogenous nitrates .
Effect of n y on
mm nt
v . Potential adverse effects could result from
prolonged nitrate therapy sufficient to induce nitrate toler-
ance. Thiol depletion could theoretically have an adverse
effect on the intracellular activation of guanylate cyclase and
the subsequent production of cyclic OMP. Some investiga-
tors have found cross-tolerance between nitroglycerin and
endothelium-derived relaxing factor with regard to both
relaxation and cyclic GMP increase (156,157) . Rapoport et
al. (157) for example, pretreated rat thoracic aortas to induce
nitrate tolerance. They then demonstrated that there was
attenuation of relaxation in response to nitroglycerin, nitro-
prusside and acetylcholine, with an associated decrease in
the formation of cyclic GMP. Other investigators have found
no cross-tolerance (158-160) . Lawson et al. (161) studied rat
aortic strips rendered nitrate tolerant and were able to
demonstrate normal relaxation in response to acetylcholine .
Thus, at this time there is inconclusive evidence to show
whether nitrate tolerance has a significant physiologically
adverse effect on endothelium-mediated events . The ques-
tion, nonetheless, has importatt clinical ramifications .
Enhanced sensitivity to nitroglycerin in the setting of
endothelial dysfunction . Most in vitro and in vivo studies
have demonstrated retained or even augmented relaxant
properties of nitrates when endothelial dysfunction is
present (155). Moncada et al . (162) recently suggested that
an enhanced sensitivity to nitrates may be present after
removal of endothelial nitric oxide . They performed in vitro
studies on isolated rat aortic rings and demonstrated that
after endothelial denudation or inhibition of endothelium-
derived relaxing factor, the potency of nitroglycerin and
nitroprusside as relaxing ents was significantly enhanced .
They also demonstrated an enhanced hypotensive response
to nitroglycerin in rats given nitric oxide synthase inhibitors
compared with rats without endothelium-derived relaxing
factor inhibition. These experiments suggested that a super-
sensitivity to nitrovasodilators at the level of soluble guany-
late cyclase was induced by the removal or inhibition of
endothelial influences . Holland et al . (163) suggested that the
endothelium is known to produce reactive oxidative metab-
olites that can scavenge nitric oxide derived from exogenous
vasodilator drugs and that its removal or inhibition might
result in an
enhanced response to exogenous nitrates as an
alternate mechanism . Either way, this has important clinical
implications .
Nitroglycerin as t for endogenous nitric oxide.
The short-term administration of nitroglycerin has been
shown to prevent endothelium-dependent constriction in
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response to exercise in patients with coronary stenoses in
vessels presumably deficient in endogenous nitric oxide . The
vasomotor response of exercise at sites of stenoses has been
shown to be vasoconstriction (84). This vasoconstriction
paralleled changes seen in response to acetylcholine and
have been interpreted to be due to endothelial dysfunction .
Cage et al . (164) also studied the effect of exercise on
vasomotion at stenotic sites in patients with angina . They
demonstrated a decrease in area of 71% at stenotic sates in
response to exercise, nitroglycerin subsequently increased
the area to 12% above control levels . In patients given
nitroglycerin before exercise, there was no decrease in area
at the stenotic site as a result of exercise . Thus, prevention
of sympathetically mediated, endothelium-dependent vaso-
constriction may be an important anti-ischemic mechanism
of nitroglycerin . Other evidence of nitroglycerin as a re-
placement for endogenous nitric oxide is lacking in humans
at this time. but the use of nitrates as surrogates for
diminished intrinsic nitric oxide would be very appealing .
However, improper tinting of nitrate administration might
deplete thiol stores, negating any potential beneficial effects
of administered nitrates .
Conclusions
The organic and inorganic nitrovasodilators share many
common features with the reccntiv discovered endothelium-
derived relaxing factor. The one major difference may be the
lack of effect of organic nitrates in the coronary microcircu-
lation. Both endothelium-derived relaxing factor and nitro-
vasodilators have similar biologic effects as a result of their
similar, final comma:,. pi 'P v y predominantly relax
vascular smooth muscle in most species and tissue beds
tested. Recent data have demonstrated the potent antiplate-
let effect of endothelium-derived relaxing factor and exoge-
nous nitrates, which may act in concert with prostacyclin .
The action of the exogenous nitrovasodilators may be en-
hanced in patients with dysfunctional endothelium, and .
conversely, nitrate tolerance may impair endothelium-
dependent processes . Much needs to be learned about the
potentially important interaction between exogenous ni-
trates and the "endogenons nitroglycerin," endothelium-
derived relaxing factor . Suet, insights might enable a more
logical use of our oldest and most prescribed antianginal
medication .
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